AbbVie to Acquire Cerevel Therapeutics for ~$8.7B
- Both AbbVie and Cerevel Therapeutics have signed a definitive agreement as per which AbbVie will acquire Cerevel for its neuroscience pipeline containing multiple clinical-stage & preclinical candidates as a potential treatment for various indications incl. Schizophrenia, Parkinson's Disease & Mood Disorders
- As per the terms of the agreement, AbbVie will acquire all outstanding shares of Cerevel for $45/share in cash, aggregating to an equity value of ~$8.7B. The transaction is expected to close by mid-2024
- Cerevel's lead assets include Emraclidine, currently undergoing P-II trial for the treatment of schizophrenia, and Tavapadon, currently under P-III evaluation for Parkinson's Disease management
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie to Acquire ImmunoGen for $10.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at email@example.com.